An interventional study of Bedrest in Muscular Atrophy, Insulin Resistance and Muscle Protein Synthesis, sponsored by Queen's University. Completed at 1 site in Canada. Open to participants aged 18 Years to 30 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by Queen's University · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies in Muscular Atrophy with a site in Canada — 1 open to participants now, 2 under way, 1 of them phase 3. Muscular Atrophy · Canada.
Among the 29 studies in Muscular Atrophy with a site in Canada, this one is the 23rd largest by enrollment of the 27 interventional ones that give a count, is the only one that started in 2025, is one of 19 with no phase, and was the 29th registered.
413 studies on the registry are indexed under Muscular Atrophy; 76 are open to participants now.
Browse Muscular Atrophy studies →1 of the 29 studies in Muscular Atrophy with a site in Canada is open now. Recruiting first, the newest first:
McMaster University · Sites in Canada
Ages 60+ · Healthy volunteers
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 51 Muscular Atrophy studies recruiting now, 25 (49%) set no upper age limit and 13 (25%) stop at 75 or younger; 4 take children under 18; 16 take healthy volunteers.
This study: 18 Years to 30 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 14 is below the median of 40 across 327 interventional studies indexed under Muscular Atrophy.
Median enrollment 26 across the 27 interventional studies, 206 across the 2 observational. Of the 26 that completed or were terminated, 4 (15%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 29 have an industry lead sponsor. The 10 most frequent:
Queen's University is the lead sponsor of 207 studies on the registry; 15 are open to participants now.
Queen's University has 2 studies filed under Muscular Atrophy — fewer than ten, so there is no comparison to draw.
1 of the studies in Muscular Atrophy with a site in Canada that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06630949McMaster UniversityD3-Creatine and Skeletal Muscle in Older Adults | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 29 studies in Muscular Atrophy with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this intervention trial is to characterize skeletal muscle atrophy in healthy, young adults during short term bedrest. The main questions it aims to answer are:
How much do skeletal muscle volume, strength, and fatigue resistance decline during bedrest? How much does whole-body insulin sensitivity change during bedrest? How do mitochondrial function and protein synthesis change during bedrest?
Participants will undergo the following tests before and after a free-living control period and before and after a 5 day period of strict horizontal bedrest:
Skeletal muscle plays a critical role in physical function and metabolic health, with its maintenance driven by the balance between muscle protein synthesis (MPS) and muscle protein breakdown (MPB). During periods of disuse, such as illness or injury, MPS declines while MPB remains relatively unchanged, leading to muscle loss and atrophy. Short-term disuse, such as bedrest, is commonly experienced through hospitalization, and can result in rapid declines in muscle mass and strength, typically affecting the lower limbs to a greater extent. At the molecular level, bed rest significantly reduces MPS, with durations as little as 3 days showing drastic impairment in skeletal muscle turnover. Additionally, short-term periods of disuse have shown to blunt mitochondrial respiration, affecting the ability for skeletal muscle to produce energy for proper funcitoning and metabolic processes. Diminished skeletal muscle metabolic function directly impacts whole-body metabolic health. Periods of bedrest between 5 and 7 days have shown to decrease whole-body glucose tolerance, increase insulin resistance, and decrease insulin-stimulated leg glucose uptake. All together, these contribute to decreased skeletal muscle mass and strength, and diminished metabolic function, contributing to a decline in overall physical function, health, and well-being. Current studies on short-term bed rest (ex. 5 days) in young adults are limited, and existing research has focused on simulated microgravity models rather than horizontal bed rest, which better represents clinical scenarios. Additionally, no study to our knowledge has explored how the molecular mechanisms that drive MPS change over the course of a 5-day bedrest period. This highlights a need to explore if there are differences in the attrition of synthesis rates of the different protein pools in skeletal muscle (ex. myofibrillar, sarcoplasmic, and mitochondrial).
The purpose of the present study is to investigate changes in leg muscle mass, strength, and whole-body insulin sensitivity over five days of bed rest, as well as examine the time-course changes in molecular mechanisms underlying skeletal muscle turnover. The investigators hypothesize that, compared to the control period, quadriceps muscle size (volume and cross-sectional area), strength/power/fatigue resistance, and whole-body insulin sensitivity will decrease following bedrest. The investigators hypothesize that these outcomes will be linked to decreases in mitochondrial respiratory function and impaired fractional synthetic rates of muscle proteins.
In this repeated-measures design, participants will undergo a five day baseline control period followed by five days of bed rest to compare changes from bedrest to their own free-living control period.
Findings from this study will help inform future research on the impact of short-term, clinically-relevant, bedrest in young adults and aid in the development of targeted interventions to mitigate declines in muscle mass from occurring from acute bouts of muscle disuse.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
19 day study period, consisting of baseline testing, 5 days of free-living (habitual daily activities) immediately followed by 5 days of strict bedrest. Diet controlled and physical activity monitored for entire study period.
Other: Bedrest
5 days of strict bedrest. Participants are allowed to sit up in bed, but will perform any bathing or bathroom activities in a wheelchair.
Also known as: Horizontal Bedrest
Quadriceps muscle volume
Quadriceps muscle volume will be assessed by magnetic resonance imaging.
Time frame: Day 0, and 5
Muscle strength
Knee extensor peak torque will be assessed using dynamometry
Time frame: Day -14, -9, and 5
Knee extensor power
Peak isotonic power determined at 30% maximal isometric voluntary contraction torque using a dynamometer
Time frame: Day -14, -9, and 5
Muscle fatiguability
Knee extensor fatiguability will be determined by the decrease in isotonic power across 40 contractions at 30% MVC using dynamometry.
Time frame: Day -14, -9, and 5
Muscle cross-sectional area
Change in quadriceps muscle cross sectional area measured by magnetic resonance imaging scan.
Time frame: Day 0 and 5
Muscle protein synthesis
Muscle protein synthesis measured as fractional synthesis rate of the myofibrillar, sarcoplasmic, and mitochondrial protein pools within skeletal muscle. These 3 pools will be assessed using combined protocol of skeletal muscle biopsy, stable isotope tracing, cavity ring down spectroscopy with liquid isotope analysis, and gas-chromatography pyrolysis isotope-ratio mass spectrometry.
Time frame: Day -5 to 0, day 0 to 1, day 0 to 3, day 0 to 5, day 1 to 3, day 1 to 5, and day 3 to 5.
2-hour plasma glucose incremental area under the curve
Determination of the total rise in plasma glucose during a mixed meal tolerance test, to be assessed by an enzyme-linked immunosorbent assay.
Time frame: Aggregate 2-hour window on day -5, 0, and 5
2- hour plasma insulin incremental area under the curve
Determination of the total rise in plasma insulin during a mixed meal tolerance test, to be assessed by an enzyme-linked immunosorbent assay.
Time frame: Aggregate 2-hours on day -5, 0, and 5
Postprandial glucose oxidation
Measurement of 13C excretion in breath samples using isotope ratio mass spectrometry.
Time frame: Aggregate 3 hours during the mixed meal tolerance test on day -5, 0, and 5
Matsuda Index
Insulin sensitivity measured via the Matsuda Index during a mixed meal tolerance test. Matsuda index values \<4.0 indicate insulin resistance, with higher values representing insulin sensitivity.
Time frame: 2-hours on day -5, 0, and 5
Mitochondrial Respiratory Function
Mitochondrial respiration will be assessed using an Oroboros Oxygraph 2000.
Time frame: Day -5, 1, 3, and 5
Expression of Translational Factors Related to Skeletal Muscle Protein Synthesis
Activation of translational factors involved in skeletal muscle protein synthesis assessed by western blotting.
Time frame: Day 0, 1, 3, and 5
Plasma glucose concentration
Plasma glucose concentration measured during a mixed meal tolerance test.
Time frame: 2-hour mixed meal tolerance test on day -5, 0, and 5
Serum insulin concentration
Serum insulin concentration measured during a mixed meal tolerance test
Time frame: 2-hour mixed meal tolerance test on day -5, 0, and 5
Peak glucose concentration
Peak glucose concentration measured during a mixed meal tolerance test
Time frame: 2-hour mixed meal tolerance test on day -5, 0, and 5
Peak insulin concentration
Peak insulin concentration measured during a mixed meal tolerance test.
Time frame: 2-hour mixed meal tolerance test on day -5, 0, and 5
Transmission Electron Microscopy Analysis
Imaging of subsarcolemmal and intermyofibrillar mitochondria to assess change in mitochondrial content from bedrest.
Time frame: Day 0, 1, 3, and 5
Supine to Stand Test
Orthostatic blood pressure assessment pre and post bedrest, and following recovery after bedrest
Time frame: Day 0, 5
Homeostatic Model Assessment for Insulin Resistance (HOMA-IR)
Insulin resistance assessed using fasting insulin and glucose levels. Values \<1.0 indicate insulin sensitivity, \>1.9 and \< 2.9 indicates early insulin resistance, and values \>2.9 indicate significant insulin resistance
Time frame: Day -5, 0, and 5
Plan to share: No
No publications or documents are linked to this record.
Ran from Sep 2025 to primary completion in Jun 2026, 9 months.
Of 170 non-industry interventional studies with no phase under Muscular Atrophy, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 38. This study's 9 months is below that.
Counting every sponsor, half of 176 studies reached it within 21 months; a quarter within 9 and three quarters within 37.
Completion moved once since we started tracking on Sep 25, 2026: Jun 2027 → Jun 2026, on Nov 12, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.